Pieris Pharmaceuticals (FRA:PI60) ROCE % : -87.23% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Pieris Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pieris Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was -87.23%.

Pieris Pharmaceuticals ROCE % Historical Data

The historical data trend for Pieris Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pieris Pharmaceuticals ROCE % Chart

Pieris Pharmaceuticals Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-26.47

-32.65

-53.51

-45.41

-27.99

Pieris Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-109.04	31.36	29.79	-75.70	-87.23

Pieris Pharmaceuticals ROCE % Calculation

Pieris Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-11.217	/	( ( (90.143 - 34.534)	+	(35.47 - 10.932) )	/ 2 )
	=	-11.217	/	( (55.609	+	24.538)	/ 2 )
	=	-11.217	/	40.0735
	=	-27.99 %

Pieris Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-19.516	/	( ( (35.47 - 10.932)	+	(27.137 - 6.93) )	/ 2 )
	=	-19.516	/	( ( 24.538	+	20.207 )	/ 2 )
	=	-19.516	/	22.3725
	=	-87.23 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Pieris Pharmaceuticals (FRA:PI60) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pieris Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Pieris Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pieris Pharmaceuticals (FRA:PI60) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pieris Pharmaceuticals Inc (FRA:PI60) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PIRS:USA PI6:Germany

Address

225 Franklin Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.pieris.com

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.

Pieris Pharmaceuticals (FRA:PI60) Headlines

No Headlines